CRESTA, FEDERICO
 Distribuzione geografica
Continente #
EU - Europa 1.334
Totale 1.334
Nazione #
IT - Italia 1.334
Totale 1.334
Città #
Genova 704
Genoa 291
Vado Ligure 170
Rapallo 167
Bordighera 2
Totale 1.334
Nome #
Abnormal activation of calpain and protein kinase Cα promotes a constitutive release of matrix metalloproteinase 9 in peripheral blood mononuclear cells from cystic fibrosis patients 178
Evidence for alteration of calpain/calpastatin system in PBMC of cystic fibrosis patients 165
Calpain inhibition promotes the rescue of F(508)del-CFTR in PBMC from cystic fibrosis patients. 157
Pathological role of the calpain/calpastatin system in cystic fibrosis 141
The calpain-calpastatin system in cystic fibrosis: physiopathological implications 124
The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin 115
Verso un approccio personalizzato per il trattamento del difetto di base in Fibrosi Cistica 108
Ionocytes and CFTR Chloride Channel Expression in Normal and Cystic Fibrosis Nasal and Bronchial Epithelial Cells 77
The L467F-F508del Complex Allele Hampers Pharmacological Rescue of Mutant CFTR by Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients: The Value of the Ex Vivo Nasal Epithelial Model to Address Non-Responders to CFTR-Modulating Drugs 62
A case of interference in testosterone, DHEA-S and progesterone measurements by second generation immunoassays 59
Rescue by elexacaftor-tezacaftor-ivacaftor of the G1244E cystic fibrosis mutation's stability and gating defects are dependent on cell background 39
Simultaneous Quantification of Ivacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis Patients’ Plasma by a Novel LC–MS/MS Method 38
Modulation of Plasmatic Matrix Metalloprotease 9: A Promising New Tool for Understanding the Variable Clinical Responses of Patients with Cystic Fibrosis to Cystic Fibrosis Transmembrane Conductance Regulator Modulators 28
Therapeutic monitoring of Ivacaftor, Tezacaftor and Elexacaftor in patients with cystic fibrosis|Monitoraggio terapeutico di Ivacaftor, Tezacaftor e Elexacaftor in pazienti con fibrosi cistica 22
QUANTIFICATION OF IVACAFTOR, TEZACAFTOR, AND ELEXACAFTOR IN PLASMA OF CYSTIC FIBROSIS PATIENTS BY AN HPLC–MS/MS METHOD 15
Quantification of Ivacaftor, Tezacaftor and Elexacaftor in plasma of cystic fibrosis patients treated with Kaftrio by a validated liquid chromatography-tandem mass spectrometric (LC-MS/MS) method” 14
Efficacy of advanced hybrid closed loop systems in cystic fibrosis related diabetes: a pilot study 11
One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study 11
Pharmacological rescue of the G85E CFTR variant by preclinical and approved modulators 9
Totale 1.373
Categoria #
all - tutte 4.824
article - articoli 3.569
book - libri 0
conference - conferenze 896
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.289


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020106 0 0 0 0 0 0 0 16 20 31 32 7
2020/202199 5 5 17 10 1 9 12 7 8 7 9 9
2021/2022143 2 3 16 8 4 8 8 30 4 15 25 20
2022/2023207 13 22 0 29 18 31 4 16 37 3 33 1
2023/2024141 5 10 6 19 17 26 6 8 2 4 16 22
2024/2025297 16 29 22 32 34 61 33 70 0 0 0 0
Totale 1.373